Are Subgroup Analysis and Sample Size Considerations Adequate in the TESTS Trial?
Dear Editor:We greatly appreciate the insights from your multicenter trial on thymosin α1 for sepsis and seek clarification on two key aspects to deepen our understanding of the findings. First, regarding the subgroup analysis showing potential differential effects by age (hazard ratio 1.67 for <60 years vs. 0.81 for ≥60 years, P for interaction=0.01) and […]
